Vor Biopharma (NASDAQ:VOR) Stock Price Up 6.2% – Should You Buy?

Vor Biopharma Inc. (NASDAQ:VOR)’s stock price traded up 6.2% on Wednesday . The company traded as high as $24.01 and last traded at $24.04. Approximately 79,561 shares traded hands during trading, a decline of 92% from the average session volume of 1,036,914 shares. The stock had previously closed at $22.64.

Wall Street Analysts Forecast Growth

Several analysts have commented on VOR shares. HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Vor Biopharma in a research note on Monday, May 18th. Weiss Ratings upgraded Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Tuesday, August 11th. Wedbush lifted their target price on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Finally, Wall Street Zen raised Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.38.

Vor Biopharma Trading Down 2.1%

The firm’s 50-day moving average price is $21.10 and its 200-day moving average price is $17.01.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). As a group, sell-side analysts anticipate that Vor Biopharma Inc. will post -2.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Several large investors have recently modified their holdings of the stock. RA Capital Management L.P. raised its holdings in Vor Biopharma by 172.7% during the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after buying an additional 3,422,697 shares during the period. Fcpm Iii Services B.V. boosted its stake in Vor Biopharma by 852.8% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after buying an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. bought a new position in Vor Biopharma during the fourth quarter valued at $33,275,000. Paradigm Biocapital Advisors LP purchased a new stake in shares of Vor Biopharma in the fourth quarter valued at $22,890,000. Finally, NEXTBio Capital Management LP bought a new stake in shares of Vor Biopharma in the 4th quarter worth about $13,080,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).